Share this article

US-based Lantheus Holdings has entered into a strategic partnership with France-based CarThera to expand the use of its microbubbles for treatment of glioblastoma, an aggressive form of brain cancer.

The agreement is part of Lantheus’ strategy to expand its microbubble franchise into the field of oncology.

Under the agreement, Lantheus’ microbubbles will be used in combination with CarThera’s patented SonoCloud System.

SonoCloud is an implantable device in development to treat recurrent glioblastoma. It leverages low-intensity pulsed ultrasound (LIPU) to facilitate optimal penetration of chemotherapy drugs in the brain.

As part of the agreement, CarThera will handle all regulatory filings, approvals and commercialisation of SonoCloud in the US and Europe, as well as other parts of the world.

Lantheus will supply its microbubble vials, ultrasound resonator and activation devices at a predetermined price.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Based on regulatory approvals, Lantheus will also receive royalties on future sales of the SonoCloud kit.

Lantheus president and CEO Mary Anne Heino said: “We are excited to collaborate with CarThera to extend our microbubble franchise into the oncology field to target glioblastoma, an aggressive type of brain cancer with significant unmet medical need,”

“Our collaboration leverages both companies’ strengths to bring novel solutions to the healthcare community. As the use of microbubbles in diagnostic and therapeutic applications gains more interest around the world, our collaboration with CarThera demonstrates our commitment to drive Lantheus’ microbubble into new disease areas with great potential for significant improvement in patient outcomes.”

Currently, CarThera’s implantable ultrasound device SonoCloud-9 System is under the Phase IIa clinical trial evaluation process.

The trial, conducted among 21 patients, will evaluate the safety and efficacy of SonoCloud-9 to cover the entire tumour and surrounding infiltrative areas.